| 101 |
23942066 | Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI. | 2013 Sep 17 |
3 |
| 102 |
24045180 | Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. | 2013 Nov 15 |
1 |
| 103 |
24063423 | Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC. | 2013 Jun |
2 |
| 104 |
22048237 | Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. | 2012 Jan 15 |
2 |
| 105 |
22090271 | The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. | 2012 Feb |
2 |
| 106 |
22260668 | Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. | 2012 Feb |
4 |
| 107 |
22271687 | Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). | 2012 Apr 1 |
1 |
| 108 |
22275507 | Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. | 2012 Mar 15 |
1 |
| 109 |
22293660 | A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244). | 2012 Aug |
4 |
| 110 |
22313687 | Enhancing CHK1 inhibitor lethality in glioblastoma. | 2012 Apr |
1 |
| 111 |
22336587 | Inhibition of metadherin sensitizes breast cancer cells to AZD6244. | 2012 Jan 1 |
1 |
| 112 |
22343622 | The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. | 2012 Feb 28 |
3 |
| 113 |
22363658 | DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. | 2012 |
1 |
| 114 |
22394161 | Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. | 2012 Apr |
1 |
| 115 |
22395615 | Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. | 2012 Mar 6 |
2 |
| 116 |
22569000 | Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. | 2012 May 8 |
2 |
| 117 |
22765220 | Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. | 2012 Jul 5 |
1 |
| 118 |
22915752 | PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. | 2012 Nov |
1 |
| 119 |
23372439 | (18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors. | 2012 May |
3 |
| 120 |
20127139 | A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. | 2011 Oct |
2 |
| 121 |
20978926 | Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). | 2011 Oct |
2 |
| 122 |
21447798 | Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. | 2011 Mar 29 |
3 |
| 123 |
21519026 | Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. | 2011 Jun 10 |
1 |
| 124 |
21642769 | Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death. | 2011 Aug 1 |
2 |
| 125 |
21674991 | A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook. | 2011 |
3 |
| 126 |
21690569 | Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition. | 2011 Aug 1 |
1 |
| 127 |
21727212 | Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. | 2011 Jul |
2 |
| 128 |
21910575 | Inhibitor of MEK1/2, selumetinib, for biliary tract cancer. | 2011 Oct |
2 |
| 129 |
21911831 | Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. | 2011 Nov 10 |
2 |
| 130 |
21953275 | A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. | 2011 Dec |
1 |
| 131 |
19634052 | Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours. | 2010 |
1 |
| 132 |
19804833 | Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244. | 2010 Jan |
3 |
| 133 |
20103661 | Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. | 2010 Feb 1 |
1 |
| 134 |
20179232 | The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. | 2010 Mar 1 |
2 |
| 135 |
20215513 | Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). | 2010 Mar 15 |
3 |
| 136 |
20484037 | Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. | 2010 Jun 1 |
1 |
| 137 |
20806365 | Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. | 2010 Oct |
2 |
| 138 |
20885957 | Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. | 2010 Sep 27 |
2 |
| 139 |
20923857 | Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. | 2010 Dec |
3 |
| 140 |
20959481 | Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. | 2010 Nov 1 |
1 |
| 141 |
19637312 | Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. | 2009 Nov 15 |
4 |
| 142 |
19843666 | The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts. | 2009 Nov 1 |
1 |
| 143 |
19915144 | MEK1 mutations confer resistance to MEK and B-RAF inhibition. | 2009 Dec 1 |
1 |
| 144 |
17983653 | Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene. | 2008 Jun |
1 |
| 145 |
18347148 | Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. | 2008 Mar |
1 |
| 146 |
18390968 | Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. | 2008 May 1 |
2 |
| 147 |
18806830 | Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. | 2008 Dec 4 |
1 |
| 148 |
17332304 | Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. | 2007 Mar 1 |
1 |
| 149 |
17392524 | Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. | 2007 Jun |
1 |
| 150 |
17878251 | Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. | 2007 Dec |
3 |